Jump to:
Arecor Therapeutics PLC Fundamentals
| Company Name | Arecor Therapeutics PLC | Last Updated | 2025-01-17 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 37.757 m | Market Cap | £22.09 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.28 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0270 | Debt Equity Ratio | 0.0333 |
|---|
| Asset Equity Ratio | 2.0414 | Cash Equity Ratio | 0.5012 |
|---|
| Quick Ratio | 0.9430 | Current Ratio | 1.37 |
|---|
| Price To Book Value | 4.3497 | ROCE | 0 |
|---|
Arecor Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Arecor Therapeutics PLC Company Financials
| Assets | 2023 | 2022 |
|---|
| Tangible Assets | £834,000.00 | £838,000.00 |
| Intangible Assets | £3.30 m | £3.40 m |
| Investments | 0 | 0 |
| Total Fixed Assets | £4.21 m | £4.29 m |
| Stocks | £771,000.00 | £1.13 m |
| Debtors | £2.87 m | £1.50 m |
| Cash & Equivalents | £6.75 m | £12.81 m |
| Other Assets | 0 | 0 |
| Total Assets | £15.38 m | £21.77 m |
| Liabilities | 2023 | 2022 |
|---|
| Creditors within 1 year | £5.15 m | £3.73 m |
| Creditors after 1 year | £700,000.00 | £582,000.00 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £5.85 m | £4.31 m |
| Net assets | £9.53 m | £17.45 m |
| Equity | 2023 | 2022 |
|---|
| Called up share capital | £306,000.00 | £306,000.00 |
| Share Premium | £28.98 m | £28.98 m |
| Profit / Loss | -£8.90 m | -£10.42 m |
| Other Equity | £9.53 m | £17.45 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £9.53 m | £17.45 m |
| Ratios | 2023 | 2022 |
|---|
| Debt Ratio | £0.02 | £0.00 |
| Debt-to-Equity | £0.02 | £0.00 |
| Assets / Equity | 2.0414 | 2.0414 |
| Cash / Equity | 0.5012 | 0.5012 |
| EPS | -£0.28 | -£0.32 |
| Cash Flow | 2023 | 2022 |
|---|
| Cash from operating activities | -£5.84 m | -£10.78 m |
| Cashflow before financing | -£6.02 m | -£5.62 m |
| Increase in Cash | £499,000.00 | -£13.61 m |
| Income | 2023 | 2022 |
|---|
| Turnover | £4.57 m | £2.40 m |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -£9.18 m | -£10.51 m |
| Pre-Tax profit | -£8.90 m | -£10.42 m |
Arecor Therapeutics PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, Germany, Italy, the Rest of Europe, the USA, and India, out of which the majority is from the UK. |
|---|
| Latest Interim Date | 26 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 16 May 2024 |
|---|
Arecor Therapeutics PLC Directors
| Appointed | Name | Position |
|---|
| 2024-08-09 | Mr. Alan Edward Smith CBE | Non-Executive Director |
| 2024-05-31 | Ms. Christine Helen Soden | Non-Executive Director |
| 2024-08-09 | Dr. Andrew John McGlashan Richards CBE | Non-Executive Director,Chairman |
| 2024-07-22 | Ms. Susan Day Lowther | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-08-09 | Mr. Mohammad Sohail Fazeli | Non-Executive Director |
| 2024-12-02 | Ms. Sarah Jennifer Howell | Executive Director,Chief Executive Officer |
| 2024-05-31 | Mr. Jeremy Lewis Morgan | Non-Executive Director |
Arecor Therapeutics PLC Contact Details
Arecor Therapeutics PLC Advisors
